Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell anemia
Biotech
Pfizer axes 3 drugs but eyes extra $25B in 2030 via outside work
Albert Bourla said it's "not the time to disrupt the momentum of the company" as Pfizer eyes $25B in additional 2030 revenue via outside science.
Kyle LaHucik
Feb 8, 2022 12:13pm
Sanofi tears up Sangamo deal in pivot to off-the-shelf approach
Jan 6, 2022 8:30am
Garuda bags $72M to advance off-the-shelf stem cell transplants
Sep 23, 2021 8:00am
Vertex adds to CRISPR fever with $1.2B Arbor gene-editing pact
Aug 24, 2021 7:00am
Fulcrum sees 'proof of biology' in phase 1 sickle cell data
Aug 11, 2021 10:10am
Graphite files for $100M IPO to fund push to cure sickle cell
Jun 8, 2021 8:30am
